Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
09 2019
Historique:
received: 11 10 2018
revised: 27 03 2019
accepted: 10 04 2019
pubmed: 4 7 2019
medline: 6 2 2020
entrez: 4 7 2019
Statut: ppublish

Résumé

We assessed the prevalence and risk factors associated with virological failure among female sex workers living with HIV on antiretroviral therapy (ART) in Kampala, Uganda. We conducted a cross-sectional study between January 2015 and December 2016 using routinely collected data at a research clinic providing services to women at high risk of STIs including HIV. Plasma samples were tested for viral load from HIV-seropositive women aged ≥18 years who had been on ART for at least 6 months and had received adherence counselling. Samples from women with virological failure (≥1000 copies/mL) were tested for HIV drug resistance by population-based sequencing. We used logistic regression to identify factors associated with virological failure. Of 584 women, 432 (74%) with a mean age of 32 (SD 6.5) were assessed, and 38 (9%) were found to have virological failure. HIV resistance testing was available for 78% (28/38), of whom 82.1% (23/28) had at least one major drug resistance mutation (DRM), most frequently M184V (70%, 16/23) and K103N (65%, 15/23). In multivariable analysis, virological failure was associated with participant age 18-24 (adjusted OR (aOR)=5.3, 95% CI 1.6 to 17.9), self-reported ART non-adherence (aOR=2.6, 95% CI 1.2 to 5.8) and baseline CD4+ T-cell count ≤350 cells/mm A relatively low prevalence of virological failure but high rate of DRM was found in this population at high risk of transmission. Younger age, self-reported ART non-adherence and low CD4+ T-cell count on ART initiation were associated with increased risk of virological failure.

Identifiants

pubmed: 31266818
pii: sextrans-2018-053854
doi: 10.1136/sextrans-2018-053854
pmc: PMC6824617
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

405-411

Subventions

Organisme : Medical Research Council
ID : MC_UU_00027/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A910_1113
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00027/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00027/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : R25 MH064712
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH123256
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
PLoS One. 2015 Dec 23;10(12):e0145536
pubmed: 26700639
AIDS Behav. 2014 Jun;18(6):1114-23
pubmed: 24368630
PLoS One. 2017 Dec 15;12(12):e0188606
pubmed: 29244809
Sex Transm Infect. 2014 Aug;90(5):418-22
pubmed: 24523347
Sex Transm Dis. 2011 Apr;38(4):316-23
pubmed: 23330152
Clin Ther. 1999 Jun;21(6):1074-90; discussion 1073
pubmed: 10440628
AIDS. 2007 Jul;21 Suppl 4:S89-95
pubmed: 17620758
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573
pubmed: 29771783
PLoS One. 2018 Sep 19;13(9):e0201352
pubmed: 30231030
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):83-90
pubmed: 27513573
PLoS One. 2016 Jan 25;11(1):e0147662
pubmed: 26808043
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Trop Med Int Health. 2016 Jul;21(7):928-35
pubmed: 27125473
AIDS Behav. 2018 Mar;22(3):1053-1061
pubmed: 29127534
Clin Infect Dis. 2006 Jun 1;42(11):1608-18
pubmed: 16652319
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):375-382
pubmed: 27930599

Auteurs

Gertrude Namale (G)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda gertrude.namale@mrcuganda.org.

Onesmus Kamacooko (O)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Daniel Bagiire (D)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Yunia Mayanja (Y)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Andrew Abaasa (A)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

William Kilembe (W)

Rwanda Zambia HIV Research Group, Emory University, Lusaka, Zambia.

Matt Price (M)

Medical Affairs, International AIDS Vaccine Initiative, New York City, New York, USA.
University of California, San Francisco, California, USA.

Deogratius Ssemwanga (D)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Sandra Lunkuse (S)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Maria Nanyonjo (M)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

William Ssenyonga (W)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Philippe Mayaud (P)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.
London School of Hygiene and Tropical Medicine, London, UK.

Rob Newton (R)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.
University of York, York, UK.

Pontiano Kaleebu (P)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.

Janet Seeley (J)

MRC/UVRI and LSHTM Uganda Research Unit, Kampala, Uganda.
London School of Hygiene and Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH